Karyopharm Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 39 U.S.-traded ETFs. KPTI has around 5.9M shares in the U.S. ETF market. The largest ETF holder of KPTI is the SPDR S&P Biotech ETF (XBI), with approximately 1.92M shares. Investors may also find of interest that the ETF with the largest allocation to KPTI stock is Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a portfolio weight of 2.45%. On average, U.S. ETFs allocate 0.26% of KPTI to their portfolios.
Additionally, KPTI is a favorite stock for Vanilla and Exchange-specific ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with KPTI as a holding is the Invesco DWA NASDAQ Momentum ETF (DWAQ), with a return of 17.61%.